SEC Form 4 filed by Executive Vice President Sahni Payal

$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PFE alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SAHNI PAYAL

(Last) (First) (Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY

(Street)
NEW YORK NY 10001-2192

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
09/12/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Rights $42.3 09/12/2024 D 45,920(1) 02/23/2028 02/23/2028 Common Stock 45,920 $0.0000 0.0000 D
Stock Appreciation Rights $42.3 09/12/2024 A 45,920(1) 02/23/2030 02/23/2030(2) Common Stock 45,920 $0.0000 45,920 D
Stock Appreciation Rights $45.96 09/12/2024 D 42,265(1) 02/24/2027 02/24/2027 Common Stock 42,265 $0.0000 0.0000 D
Stock Appreciation Rights $45.96 09/12/2024 A 42,265(1) 02/24/2029 02/24/2029(2) Common Stock 42,265 $0.0000 42,265 D
Explanation of Responses:
1. Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.
2. Reflects a modification to the settlement date of the Modified TSRUs pursuant to the Modification Offer. The grant price and number of shares underlying the Modified TSRUs remain unchanged.
Susan E. Grant, by power of atty., for Payal Sahni 09/16/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $PFE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PFE

DatePrice TargetRatingAnalyst
12/10/2024$29.00Neutral
BofA Securities
11/15/2024$25.00Underperform
Wolfe Research
10/25/2024$30.00Neutral
Citigroup
10/17/2024$32.00Mkt Perform
Bernstein
8/7/2024Neutral → Outperform
Daiwa Securities
3/22/2024Buy → Hold
Argus
2/23/2024$36.00Buy
Guggenheim
1/4/2024$32.00Outperform → Market Perform
TD Cowen
More analyst ratings

$PFE
Press Releases

Fastest customizable press release news feed in the world

See more
  • Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

    Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population Treatment naïve high-risk NMIBC is an area of significant unmet need, where therapeutic options have largely remained unchanged for over three decades Pfizer Inc. (NYSE:PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. Abou

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Stuart Therapeutics Announces the Appointment of Two New Board Members

    Stuart Therapeutics adds recognized leaders in ophthalmology therapeutics development, commercialization. STUART, Fla., Dec. 22, 2024 /PRNewswire/ -- Stuart Therapeutics announced today the appointment of Tracy Valorie and Jason Werner to the company's Board of Directors, bringing the total number of Board members to five. These new Directors will hold the positions previously held by Robert O. Baratta, MD, who passed away suddenly in the third quarter of this year, and retired US Representative Diane Black, RN, who recently resigned her position on the company's Board. Tracy

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PFE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PFE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PFE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PFE
SEC Filings

See more

$PFE
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PFE
Leadership Updates

Live Leadership Updates

See more
  • Stuart Therapeutics Announces the Appointment of Two New Board Members

    Stuart Therapeutics adds recognized leaders in ophthalmology therapeutics development, commercialization. STUART, Fla., Dec. 22, 2024 /PRNewswire/ -- Stuart Therapeutics announced today the appointment of Tracy Valorie and Jason Werner to the company's Board of Directors, bringing the total number of Board members to five. These new Directors will hold the positions previously held by Robert O. Baratta, MD, who passed away suddenly in the third quarter of this year, and retired US Representative Diane Black, RN, who recently resigned her position on the company's Board. Tracy

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pfizer Announces New Chief Scientific Officer and President, Research & Development

    Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer Pfizer Inc. (NYSE:PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer wa

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Tim Buckley Elected to Pfizer's Board of Directors

    Pfizer Inc. (NYSE:PFE) today announced the election of Mortimer ("Tim") J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent. Mr. Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024. Previously he was Vanguard's Chief Investment Officer, overseeing the company's internally managed stock, bond and money market portf

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PFE
Financials

Live finance-specific insights

See more
  • Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also liste

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

    Full-Year 2025 Revenue Guidance(1) Range of $61.0 to $64.0 Billion Full-Year 2025 Adjusted(2) Diluted EPS Guidance Range of $2.80 to $3.00 Expect Full-Year 2025 Adjusted(2) Diluted EPS Operational(3) Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items(4) Achieved Goal of $4.0 Billion in Net Cost Savings Through 2024 and Anticipate an Additional $500 Million in Savings in 2025 from Ongoing Cost Realignment Program First Phase of Manufacturing Optimization Program On Track to Deliver Initial Net Cost Savings in the Latter Part of 2025, Toward Goal of Improving Gross Margin Performance Pfizer Inc. (NYSE:PFE) today provided its fu

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pfizer Declares First-Quarter 2025 Dividend

    Board of Directors approves increase in quarterly cash dividend to $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer. "Our decision to increase our quarterly dividend underscores our strong financial performance, disciplined execution and our commitment to returning value to our shareholders," said Dr. Albert Bourla, Pfiz

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PFE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more